Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Alzheimer Disease: HELP
William Z. Potter
Based on 16 articles published since 2010
(Why 16 articles?)
||||
Expertise Level
The expertise of William Z. Potter ranks in the
  • Top 4%
  • ... of 135,371 published authors worldwide on Alzheimer Disease
  • ... from 2010 through 2020
  • ... based on contributions to 16 articles on the topic.
Graphical view (beta)
Aliases Potter, W Z   ·   Potter, William   ·   Potter, W   ·   Potter, William Z
Work Locations
Details
Most likely:    National Institutes of Health      
2016
  • Alzheimer's Association, Chicago, IL, USA. · Center for Imaging of Neurodegenerative Diseases, San Francisco VA Medical Center, San Francisco, CA, USA. · National Institute of Mental Health (NIMH), Bethesda, MD, USA. · Alzheimer's & Dementia: The Journal of the Alzheimer's Association, Rockville, MD, USA. Electronic address: · Pubmed 27836052
2015
  • Clinical Memory Research Unit, Lund University, Sweden. · Alzheimer's Association, Chicago, IL, USA. · Eli Lilly & Co, Inc., Indianapolis, IN, USA. · Avid Radiopharmaceuticals, Philadelphia, PA, USA. · F. Hoffmann-La Roche, Basel, Switzerland. · Araclon Grifols, Zaragoza, Spain. · AztraZeneca, Stockholm, Sweden; Department of Clinical Neuroscience, Karolinska Institutet, Sweden. · Foundation for the NIH, Bethesda, MD, USA. · Brigham and Women's Hospital, Boston, MA, USA. · Washington University School of Medicine, St. Louis, MO, USA. · Elverson, PA, USA. · Janssen Research and Development, LLC., San Diego, CA, USA. · Pubmed 27239522
  • Neuroscience Biomarkers, Discovery, Janssen Research and Development, San Diego, CA, USA. Electronic address: · Neuroscience Clinical Development, Clinical Neuroscience Eisai, Woodcliff Lake, NJ, USA. · Clinical Development, Biogen, Cambridge, MA, USA. · Experimental Medicine, Janssen Pharmaceutica NV, Beerse, Belgium. · Clinical and Translational Science, Imaging, Takeda Pharmaceuticals, Inc, Deerfield, IL, USA. · Medical and Scientific Relations, Alzheimer's Association, Chicago, IL, USA. · Foundation for the NIH, Bethesda, MD, USA. · Neuroscience Clinical Development, Janssen Research and Development, Titusville, NJ, USA. · Medical Affairs, Piramal Pharma Inc, Boston, MA, USA. · Clinical Biomarkers, Bristol-Meyer Squibb, Hopewell, NJ, USA. · Office of the Director, National Institute of Mental Health, Rockville, MD, USA. · Biomedicines Business Unit, Alzheimer's Disease Platform Team, Eli Lilly and Company, Indianapolis, IN, USA. · Tailored Therapeutics, Eli Lilly and company, Indianapolis, IN, USA. · Pubmed 26194317
  • Merck and Company, West Point, PA, USA. · Eisai, Woodcliff Lake, NJ, USA. · National Institute of Mental Health, Bethesda, MD, USA. · Pubmed 25790831
  • Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Pennsylvania, PA, USA. · Department of Pharmacodynamic Biomarkers within Development Sciences, Genentech, Inc (a member of the Roche Group), South San Francisco, CA, USA. · Discovery Sciences, Janssen Research & Development LLC, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium. · Janssen Research & Development LLC, Titusville, NJ, USA. · Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. · Caprion Pharmaceuticals, Montreal, QC, Canada. · Foundation for the National Institutes of Health, Inc, Bethesda, MD, USA. · National Institute of Mental Health, Bethesda, MD, USA. · Pubmed 25676562
2014
  • Division of Medical and Scientific Relations, Alzheimer's Association, Chicago, IL. · Department of Neurosciences, University of California San Diego School of Medicine, San Diego, CA. · Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD. · Department of Neurology and Framingham Heart Study, Boston University School of Medicine, Boston, MD. · Department of Neurology and Department of Epidemiology, University of California, Irvine, CA. · Department of Neurology, University of Virginia, Charlottesville, VA; Department of Radiology and Department of Neurology, University of Pittsburgh, PA. · Department of Neurology, University of Massachusetts Medical School, Worcester, MA. · Alzheimer's Drug Discovery Foundation; Department of Geriatrics and Palliative Medicine and Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY. · Department of Community-Public Health and Department of Psychiatry, Johns Hopkins University, Baltimore, MD. · Orion Bionetworks, Cambridge, MA. · Division of Life Science and the State Key Laboratory of Molecular Neuroscience, Hong Kong University of Science and Technology, Kowloon, Hong Kong. · Department of Neurology, Department of Neurobiology & Behavior, and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA. · National Biomedical Research Ethics Council, Rockville, MD. · PAD2020, Rockville, MD. · Department of Psychiatry, University of Pittsburgh, PA. · Department of Neurology, Mayo Clinic Alzheimer's Disease Research Center, Mayo Clinic College of Medicine, Rochester, MN. · National Alzheimer's Coordinating Center (NACC); and Department of Epidemiology, University of Washington, Seattle, WA. · Department of Neurosciences, Lerner Research Institute, The Cleveland Clinic, Cleveland, OH. · Department of Psychosocial and Community Health, University of Washington, Seattle, WA. · Florey Institute for Neuroscience and Mental Health, University of Melbourne; and CogState Ltd., Melbourne VIC, Australia. · Department of Neurology and Alzheimer's Disease Center, Feinberg School of Medicine, Northwestern University, Chicago, IL. · Neuroscience Early Clinical Development, Eli Lilly and Company, Indianapolis, IN. · Byrd Alzheimer's Institute, University of South Florida, Tampa, FL. · Department of Psychiatry and Department of Cell Biology, New York University Langone Medical Center, New York, NY; and The Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY. · Appel Alzheimer's Disease Research Institute, Weill Cornell Medical College, New York, NY; Foundation for the National Institutes of Health, Bethesda, MD. · Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC. · Neuroscience Steering Committee of the Biomarkers Consortium, Foundation of the National Institutes of Health (emeritus). · Banner Alzheimer's Institute; and Department of Psychiatry, University of Arizona College of Medicine, Phoenix, AZ. · Department of Psychiatry, New York University School of Medicine, New York, NY. · Department of Psychiatry; and Alzheimer's Disease Research Center, Mount Sinai School of Medicine, New York, NY. · Pfizer, Inc., New York, NY. · Department of Psychiatry and the Behavioral Sciences and Department of Neurology, Keck School of Medicine; and Leonard Davis School of Gerontology; University of Southern California, Los Angeles, CA. · Department of Neurology, Alpert Medical School of Brown University; and Department of Neurology, Rhode Island Hospital; Providence, RI. · Departments of Neurology, Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA. · Department of Psychiatry and Department of Neurology, University of California, San Francisco; and San Francisco VA Medical Center, CA. · Independent Science Writer, Elverson, PA. · Division of Medical and Scientific Relations, Alzheimer's Association, Chicago, IL. Electronic address: · Pubmed 25341459
Probable:    Merck and Co      
2015
  • Departments of Exploratory and Translational Sciences, Merck & Co., Rahway, NJ, United States of America. · Biometrics, Merck & Co., Rahway, NJ, United States of America. · Applied Computer Science and Mathematics, Merck & Co., Rahway, NJ, United States of America. · Clinical Neuroscience and Ophthalmology, Merck & Co., West Point, PA, United States of America. · Biometrics, Merck & Co., West Point, PA, United States of America. · Clinical Development Laboratory, Merck & Co., Rahway, NJ, United States of America. · Neuroscience Basic Research, Merck & Co., West Point, PA, United States of America. · OPTIMA, University of Oxford, Department of Pharmacology, Oxford United Kingdom. · Rosetta Biosoftware, Seattle, WA, United States of America. · Pubmed 26270474
  • Merck Research Laboratories, Merck & Co., Inc., Whitehouse Station, NJ, USA. · OPTIMA, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK Current address: University of Cape Town, Groote Schuur Hospital, Cape Town, ZA. · OPTIMA, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK. · OPTIMA, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK OPTIMA, Department of Pharmacology, Mansfield Rd., Oxford, UK. · Pubmed 25391385
2010
Show More
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of the 10 most recent articles (out of 16 total) written by William Z. Potter about Alzheimer Disease:

  • The crisis in recruitment for clinical trials in Alzheimer's and dementia: An action plan for solutions. 2016
  • Revolutionizing Alzheimer's disease and clinical trials through biomarkers. 2015
  • Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB). 2015
  • High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid. 2015
  • Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort. 2015
  • Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF. 2015
  • Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. 2015
  • 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. 2014
  • Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. 2012
  • Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease. 2011
Show List of Full Article Records
Google Searches

Learn more about William Z. Potter using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
National Institutes of Health
Merck and Co
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
National Institutes of Health
2016
  • Alzheimer's Association, Chicago, IL, USA. · Center for Imaging of Neurodegenerative Diseases, San Francisco VA Medical Center, San Francisco, CA, USA. · National Institute of Mental Health (NIMH), Bethesda, MD, USA. · Alzheimer's & Dementia: The Journal of the Alzheimer's Association, Rockville, MD, USA. Electronic address: · Pubmed 27836052
2015
  • Clinical Memory Research Unit, Lund University, Sweden. · Alzheimer's Association, Chicago, IL, USA. · Eli Lilly & Co, Inc., Indianapolis, IN, USA. · Avid Radiopharmaceuticals, Philadelphia, PA, USA. · F. Hoffmann-La Roche, Basel, Switzerland. · Araclon Grifols, Zaragoza, Spain. · AztraZeneca, Stockholm, Sweden; Department of Clinical Neuroscience, Karolinska Institutet, Sweden. · Foundation for the NIH, Bethesda, MD, USA. · Brigham and Women's Hospital, Boston, MA, USA. · Washington University School of Medicine, St. Louis, MO, USA. · Elverson, PA, USA. · Janssen Research and Development, LLC., San Diego, CA, USA. · Pubmed 27239522
  • Neuroscience Biomarkers, Discovery, Janssen Research and Development, San Diego, CA, USA. Electronic address: · Neuroscience Clinical Development, Clinical Neuroscience Eisai, Woodcliff Lake, NJ, USA. · Clinical Development, Biogen, Cambridge, MA, USA. · Experimental Medicine, Janssen Pharmaceutica NV, Beerse, Belgium. · Clinical and Translational Science, Imaging, Takeda Pharmaceuticals, Inc, Deerfield, IL, USA. · Medical and Scientific Relations, Alzheimer's Association, Chicago, IL, USA. · Foundation for the NIH, Bethesda, MD, USA. · Neuroscience Clinical Development, Janssen Research and Development, Titusville, NJ, USA. · Medical Affairs, Piramal Pharma Inc, Boston, MA, USA. · Clinical Biomarkers, Bristol-Meyer Squibb, Hopewell, NJ, USA. · Office of the Director, National Institute of Mental Health, Rockville, MD, USA. · Biomedicines Business Unit, Alzheimer's Disease Platform Team, Eli Lilly and Company, Indianapolis, IN, USA. · Tailored Therapeutics, Eli Lilly and company, Indianapolis, IN, USA. · Pubmed 26194317
  • Merck and Company, West Point, PA, USA. · Eisai, Woodcliff Lake, NJ, USA. · National Institute of Mental Health, Bethesda, MD, USA. · Pubmed 25790831
  • Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Pennsylvania, PA, USA. · Department of Pharmacodynamic Biomarkers within Development Sciences, Genentech, Inc (a member of the Roche Group), South San Francisco, CA, USA. · Discovery Sciences, Janssen Research & Development LLC, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium. · Janssen Research & Development LLC, Titusville, NJ, USA. · Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. · Caprion Pharmaceuticals, Montreal, QC, Canada. · Foundation for the National Institutes of Health, Inc, Bethesda, MD, USA. · National Institute of Mental Health, Bethesda, MD, USA. · Pubmed 25676562
2014
  • Division of Medical and Scientific Relations, Alzheimer's Association, Chicago, IL. · Department of Neurosciences, University of California San Diego School of Medicine, San Diego, CA. · Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD. · Department of Neurology and Framingham Heart Study, Boston University School of Medicine, Boston, MD. · Department of Neurology and Department of Epidemiology, University of California, Irvine, CA. · Department of Neurology, University of Virginia, Charlottesville, VA; Department of Radiology and Department of Neurology, University of Pittsburgh, PA. · Department of Neurology, University of Massachusetts Medical School, Worcester, MA. · Alzheimer's Drug Discovery Foundation; Department of Geriatrics and Palliative Medicine and Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY. · Department of Community-Public Health and Department of Psychiatry, Johns Hopkins University, Baltimore, MD. · Orion Bionetworks, Cambridge, MA. · Division of Life Science and the State Key Laboratory of Molecular Neuroscience, Hong Kong University of Science and Technology, Kowloon, Hong Kong. · Department of Neurology, Department of Neurobiology & Behavior, and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA. · National Biomedical Research Ethics Council, Rockville, MD. · PAD2020, Rockville, MD. · Department of Psychiatry, University of Pittsburgh, PA. · Department of Neurology, Mayo Clinic Alzheimer's Disease Research Center, Mayo Clinic College of Medicine, Rochester, MN. · National Alzheimer's Coordinating Center (NACC); and Department of Epidemiology, University of Washington, Seattle, WA. · Department of Neurosciences, Lerner Research Institute, The Cleveland Clinic, Cleveland, OH. · Department of Psychosocial and Community Health, University of Washington, Seattle, WA. · Florey Institute for Neuroscience and Mental Health, University of Melbourne; and CogState Ltd., Melbourne VIC, Australia. · Department of Neurology and Alzheimer's Disease Center, Feinberg School of Medicine, Northwestern University, Chicago, IL. · Neuroscience Early Clinical Development, Eli Lilly and Company, Indianapolis, IN. · Byrd Alzheimer's Institute, University of South Florida, Tampa, FL. · Department of Psychiatry and Department of Cell Biology, New York University Langone Medical Center, New York, NY; and The Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY. · Appel Alzheimer's Disease Research Institute, Weill Cornell Medical College, New York, NY; Foundation for the National Institutes of Health, Bethesda, MD. · Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC. · Neuroscience Steering Committee of the Biomarkers Consortium, Foundation of the National Institutes of Health (emeritus). · Banner Alzheimer's Institute; and Department of Psychiatry, University of Arizona College of Medicine, Phoenix, AZ. · Department of Psychiatry, New York University School of Medicine, New York, NY. · Department of Psychiatry; and Alzheimer's Disease Research Center, Mount Sinai School of Medicine, New York, NY. · Pfizer, Inc., New York, NY. · Department of Psychiatry and the Behavioral Sciences and Department of Neurology, Keck School of Medicine; and Leonard Davis School of Gerontology; University of Southern California, Los Angeles, CA. · Department of Neurology, Alpert Medical School of Brown University; and Department of Neurology, Rhode Island Hospital; Providence, RI. · Departments of Neurology, Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA. · Department of Psychiatry and Department of Neurology, University of California, San Francisco; and San Francisco VA Medical Center, CA. · Independent Science Writer, Elverson, PA. · Division of Medical and Scientific Relations, Alzheimer's Association, Chicago, IL. Electronic address: · Pubmed 25341459
Merck and Co
2015
  • Departments of Exploratory and Translational Sciences, Merck & Co., Rahway, NJ, United States of America. · Biometrics, Merck & Co., Rahway, NJ, United States of America. · Applied Computer Science and Mathematics, Merck & Co., Rahway, NJ, United States of America. · Clinical Neuroscience and Ophthalmology, Merck & Co., West Point, PA, United States of America. · Biometrics, Merck & Co., West Point, PA, United States of America. · Clinical Development Laboratory, Merck & Co., Rahway, NJ, United States of America. · Neuroscience Basic Research, Merck & Co., West Point, PA, United States of America. · OPTIMA, University of Oxford, Department of Pharmacology, Oxford United Kingdom. · Rosetta Biosoftware, Seattle, WA, United States of America. · Pubmed 26270474
  • Merck Research Laboratories, Merck & Co., Inc., Whitehouse Station, NJ, USA. · OPTIMA, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK Current address: University of Cape Town, Groote Schuur Hospital, Cape Town, ZA. · OPTIMA, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK. · OPTIMA, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK OPTIMA, Department of Pharmacology, Mansfield Rd., Oxford, UK. · Pubmed 25391385
2010
7 Other Locations Show
Yearly article counts 00001610134
 
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.